Palazestrant

DB18971InvestigationalSmall molecule

Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

Mechanism: Pharmacologically active on Estrogen receptor
Curator reviewed
Formula / weight: C₂₈H₃₆FN₃O · 449.614 g/mol (avg)
Also known as: (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole · 1H-Pyrido[3,4-b]indole, 2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1-[4-[(1-propyl-3-azetidinyl)oxy]phenyl]-, (1R,3R)-
Code names: OP-1250

Resolves to

Compound

UNIIVU35KM56Q4CAS2092925-89-6

Structure

InChIKeyLBSFUBLFDCAEKV-XHCCPWGMSA-NSMILESCCCN1CC(C1)OC1=CC=C(C=C1)[C@H]1N(CC(C)(C)F)[C@H](C)CC2=C1NC1=CC=CC=C21

Targets

P03372ESR1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Palazestrant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account